Stonegate Capital Partners Updates Coverage on Sky Harbour Group Corporation (SKYH) Q1 2025
Published [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year]
Dallas, Texas--(Newsfile Corp. - May 29, 2025) - Sky Harbour Group Corp. (NYSE: SKYH): Stonegate Capital Partners updates their coverage on Sky Harbour Group Corp. (NYSE: SKYH). Sky Harbour continued to demonstrate strong momentum in 1Q25, driven by expanding its aviation infrastructure footprint and ramping operational capacity. During the quarter, the Company initiated operations at its Phoenix Deer Valley (DVT) campus and prepared for openings at Dallas Addison (ADS) and Denver Centennial (APA), scheduled for 2Q25. SKYH added a key facility at Seattle's Boeing Field (BFI), with ~90,000 sq ft of rentable space, and signed new ground leases at Hillsboro (HIO) and Stewart International (SWF), reinforcing its national footprint. As of quarter-end, the Company's portfolio included eight operational campuses, one under construction, and ten in pre-development, positioning it for significant long-term growth.
To view the full announcement, including downloadable images, bios, and more, click here .
Key Takeaways: SKYH reported total revenue of $5.6M, a 133% increase from $2.4M in 1Q24 and a 20% increase sequentially.
As of quarter-end, the Company's portfolio included eight operational campuses, one under construction, and ten in pre-development.
Sky Harbour ended 1Q25 with total assets of $553.7M. Liquidity remained strong, at $97.5M.
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/7294/253815_figure1_550.jpg ]
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
[email protected]
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253815
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
16 minutes ago
- Fast Company
UNH stock: Why are UnitedHealth Group shares surging over 11% today? It's because of this big reveal
Shares in the troubled private health insurer UnitedHealth Group (NYSE: UNH) are currently seeing their best trading day in months. As of the time of this writing, UNH shares are up nearly 11.8% to $303.94 in pre-market trading. Yet the company, which is under federal criminal and civil investigations for alleged irregularities in its Medicare business, hasn't announced any fundamental changes to its business—no revised upward outlooks or hints that its operational costs are decreasing. So why then are UNH shares surging this morning? It mainly comes down to one man: Warren Buffett. The Warren Buffett effect Warren Buffett is the most legendary investor in America, and when his company, Berkshire Hathaway, buys shares in another company, investors take notice. And that's exactly what's happened with UNH shares. In a regulatory filing with the Securities and Exchange Commission (SEC), Berkshire Hathaway has revealed that the Warren Buffett-led firm acquired a significant position in UNH in June. As noted by CNBC, Berkshire Hathaway purchased more than 5 million shares of UNH in June, worth about $1.6 billion. Now that that stake has been revealed, other investors are buying into UNH, likely hoping both to ride the Warren Buffett effect and also hoping that Buffett is correct in whatever he sees in the stock that has led Berkshire Hathaway to make such a large investment. One of the tactics Buffett, who is known as the 'Oracle of Omaha,' has used to buy stocks in the past is to invest in companies when they are down. It's a strategy many investors use: buy stocks when they are depressed, hoping they will rise in the future when the company overcomes whatever challenges it is facing and investor sentiment warms. UNH shares have still had a horrible 2025 Of course, UnitedHealth Group is facing more challenges than most companies right now. After the killing of its subsidiary's CEO, UnitedHealthcare's Brian Thompson, in December 2024, there was large blowback from the American public against UnitedHealth. Americans under UnitedHealth plans voiced their frustrations about their difficulties in getting medical appointments or treatments approved by the private insurer, not to mention the crippling medical costs they face even if their treatments are approved. The private insurance giant has also faced rising costs as more elderly Americans who delayed elective procedures during the Covid-19 pandemic are now returning to hospitals to get surgeries, such as hip and knee replacements. In May, UnitedHealth Group's CEO, Andrew Witty, announced he was stepping down. And in July, the company confirmed that it was under federal criminal and civil investigations for alleged irregularities in its Medicare business, as well as revised its 2025 full-year fiscal outlook downward. Before today's pre-market boost to its stock price, UNH shares had trended down for a long time. As of yesterday's market close, UNH shares were down over 46% year-to-date. Over the past 12 months, shares have been down over 53%. While the nearly 12% rise in UNH's share price this morning is giving the stock a much-needed boost, the company is still facing the same problems it was before Berkshire Hathaway's stake was revealed.
Yahoo
41 minutes ago
- Yahoo
Morgan Stanley Maintains a Buy on Haleon plc (HLN) With a PT of $10.95
Haleon plc (NYSE:HLN) is one of the best NYSE stocks to buy under $20. In a report released on August 4, Morgan Stanley maintained a Buy rating on Haleon plc (NYSE:HLN) with a price target of $10.95. A pharmacist and a customer discussing a novel therapeutic oral health product in a pharmacy. Haleon plc (NYSE:HLN) reported unaudited results for H1 2025 on June 30, reporting notable growth in EMEA & LatAm and Asia-Pacific, while showing continued outperformance in Oral Health. Management reported organic revenue growth across EMEA & LatAm (+5.2%) and Asia-Pacific (+5.0%), partially offsetting a 0.4% decline in North America. The trends reflected a weak US consumer and retail environment. The company also reported that 58% of businesses gained or maintained market share, suggesting the resilience of its brand portfolio. Free cash flow for the first half of the year reached £734 million, up £184 million year-on-year, primarily due to progress on working capital initiatives. Haleon plc (NYSE:HLN) provides personal healthcare products, with a focus on consumer healthcare. The company's operations are divided into the following geographical segments: North America, EMEA and LatAm, and Asia Pacific. While we acknowledge the potential of HLN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
Bank of America Securities Maintains a Hold Rating on Ambev S.A. (ABEV)
Ambev S.A. (NYSE:ABEV) is one of the best NYSE stocks to buy under $20. In a report released on August 1, Isabella Simonato from Bank of America Securities maintained a Hold rating on Ambev S.A. (NYSE:ABEV) without assigning a price target. A close-up on several cans of freshly brewed beer in a commercial brewery. The rating update followed Ambev S.A.'s (NYSE:ABEV) fiscal Q2 2025 results on July 31, with net revenue (organic) growth of 3.4% and top-line performance driven by net revenue per hectoliter (NR/hl) growth of 8.4%. Normalized EBITDA (organic) grew by 7.6% with all of the company's reporting segments delivering EBITDA growth. Management also reported that normalized profit for the quarter rose 15.2% to R$2.8327 billion compared to R$2.4591 billion in fiscal Q2 2024. This growth was attributed to lower income tax expenses and EBITDA growth, particularly offset by higher net financial results. Ambev S.A. (NYSE:ABEV) produces, distributes, and sells beverages. Its offerings include carbonated soft drinks, beer, and other non-alcoholic and non-carbonated products. The company's operations are divided into the following geographical segments: Brazil, Central America and the Caribbean (CAC), and Canada. While we acknowledge the potential of ABEV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
